Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

• Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020, the world witnessed a major acquisition of Immunomedic by Gilead of $21B for Trodelvy
• Our team at PharmaShots has compiled a list of top 20 oncology companies based on their 2020 oncology revenue
• In in the list of top 20 companies, BMS secured the top position with total revenue of $28B from oncology segment in 2020, followed by Roche and Merck with $26B & $15B

Dr.Reddy is an Indian Pharmaceutical company that is mainly involved in developing a wide range of generic formulations and proprietary products. The company focuses on multiple therapeutic areas including oncology, cardiovascular, dermatology, gastrointestinal, diabetology, pain management, and nephrology. In September 2020, Dr. Reddy’s Laboratories launched Faslodex (fulvestrant) injection which is used to treat metastatic breast cancer. The company generated a sale of $0.23B from its oncology segment in 2020.

BeiGene is a global biotechnology company that focuses mainly on developing medicines for cancer treatment. In June 2020, BeiGene reported EMA’s acceptance of its marketing authorization application for Brukinsa (zanubrutinib) for the treatment of patients with Waldenstrom’s Macroglobulinemia. In 2020, BeiGene’s key drug, Brukinsa generated total sales of $0.04B and the company generated total revenue of $0.30B from the oncology segment.

Daiichi Sankyo is a global pharmaceutical company that focuses on developing novel therapies in therapeutic areas including oncology and rare diseases. In May 2020, Daiichi Sankyo launched Enhertu in Japan for patients with metastatic breast cancer. In 2020, the company’s key drug, Trastuzumab deruxtecan (Enhertu) generated total sales of $0.39B.

GlaxoSmithKline (GSK) is a British multinational pharmaceutical company that focuses on developing therapies in areas including oncology, respiratory, and immuno-inflammation. In August 2020, FDA approved GSK’s Blenrep for the treatment of patients with relapsed or refractory multiple myeloma. With its two approved drugs, Zezula and Blenrep, GSK generated total revenue of $0.51B from its oncology segment in 2020.

Gilead Sciences is an American biopharmaceutical company that focuses on researching and developing medicines in areas including HIV/AIDS, oncology, liver diseases, and hematology, inflammatory and respiratory. In October 2020, Gilead Sciences acquired Immunomedics. Gilead’s oncology drug, Yescarta recorded total sales of $0.56B in 2020. The company generated total revenue of $0.67B from its oncology segment in 2020.

Sanofi is a French multinational pharmaceutical company that focuses on developing novel therapies for oncology, cardiovascular, neurology, immunology, and inflammation. In June 2020, European Commission approved Sarclisa (isatuximab) for adults with relapsed and refractory multiple myeloma. Sanofi’s leading oncology drug, Jevtana recorded sales of $0.65B last year. In 2020, Sanofi generated total revenue of $0.97B from its oncology segment.

Bayer is a German multinational pharmaceutical company with a focus on cancer, cardiovascular, and kidney diseases. In March 2020, Nubeqa received EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer. Bayer’s leading drug, Nexavar recorded total sales of $0.78B last year. In 2020, Bayer generated total revenue of $1.68B from its oncology segment.

Incyte is an American multinational pharmaceutical company that focuses on multiple therapeutic areas including oncology, inflammation and autoimmunity. In May 2020, the US FDA approved Tabrecta (capmatinib) for the treatment of patients with metastatic NSCLC with METex14. The leading oncology drug of the company, Jakafi recorded total sales of $1.93B while the total revenue of the company is $2.06B from its oncology segment.

Takeda is a Japanese multinational pharmaceutical company that develops innovative therapies in areas including oncology, rare diseases, and gastroenterology. In May 2020, the US FDA approved Takeda’ Alunbrig as a 1L treatment for patients diagnosed with a rare and serious form of lung cancer. Last year, the company generated total revenue of $3.76B from its oncology segment.

Astellas Pharma is a Japanese multinational pharmaceutical company that focuses on developing novel therapies for therapeutic areas including oncology, nephrology, urology, and transplantation. In 2020, Astellas acquired Audentes Therapeutics, and its product, Xtandi received Xtandi’s approval in NMPA for the treatment of non-mCRPC. Xtandi (lead drug) contributes 90% of the total oncology segment i.e $4.14B whereas Astellas generated total revenue of $4.47B from the oncology segment.

Eli Lilly is an American pharmaceutical company that deals in oncology, endocrinology, neurodegenerative diseases, immunology, pain, and migraine. In 2020, Selpercatinib (Retevmo) was granted accelerated approval by the FDA for thyroid and lung cancer. Alimta, the leading candidate of the company recorded total sales of $2.33B whereas the total revenue oncology segment is $5.31B in 2020

Abbvie is an American pharmaceutical company that focuses on developing novel products for therapeutic areas including oncology, immunology, dermatology, and virology. In 2020, Venclexta received FDA approval for AML and Imbruvica recorded total sales of $5.31B. Last year, Abbvie generated total revenue of $6.65B from its oncology segment.

Amgen is an American biopharmaceutical company that is working on multiple therapeutic areas including oncology, neurology, immunology, nephrology, and inflammation. In December 2020, FDA approved Riabni, a biosimilar to Rituxan, for the treatment of adult patients with NHL & CLL. Amgen’s key drug, Xgeva recorded total sales of $1.89B while the company generated total revenue of $8.32B from its oncology segment.

AstraZeneca is a multinational pharmaceutical and biotechnology company that focuses on a portfolio of products in areas including oncology, cardiovascular, gastrointestinal, infection, respiratory, and inflammation. In September 2020, AZ’sImfinzi was approved in the EU for 1L treatment of adults with ES-SCLC. Last year, Tagrisso recorded total sales of $4.32B while the company’s total revenue is $10.85B from its oncology segment.

Pfizer is an American multinational pharmaceutical and biotechnology company that develops novel medicines and vaccines for therapeutic areas including oncology, immunology, cardiology, endocrinology and neurology. In June 2020, the EU approved Bavencio as a treatment for patients with LA or metastatic urothelial carcinoma. Pfizer’s leading drug, Ibrance recorded 50% of the total sales of the company in the oncology segment i.e. $5.39B.

Johnson and Johnson is an American multinational pharmaceutical company that has a product portfolio of multiple therapeutic areas including CV, oncology, immunology, and endocrinology. In its oncology segment, J&J focuses on core diseases including prostate cancer and multiple myeloma. The company’s leading drug, Darzalex recorded total sales of $4.19B whereas the total revenue is $12.36B in the oncology segment.

Novartis is a Swiss multinational pharmaceutical company that works in multiple disease areas including oncology, hepatology, immunology, dermatology, musculoskeletal diseases, neuroscience, and ophthalmology. In 2020, Novartis generated total revenue of $14.71B from its oncology segment.

Merck is an American multinational pharmaceutical company focused on developing innovative medicines in areas including oncology, infectious diseases, respiratory and immunology. In 2020, FDA approved Merck’ Keytruda in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer. Keytruda recorded total sales of $14.38B whereas the total revenue of the company is $15.83B in its oncology segment.

Roche is a Swiss multinational pharmaceutical company focused on developing products in areas including oncology, immunology, and ophthalmology, cardiovascular and respiratory. In December 2020, EC approved Roche’ Phesgo for people with HER2- breast cancer. Roche’s Avastin recorded total sales of $5.64B whereas the company generated total revenue of $26.37B from its oncology segment.

BMS is a global biopharmaceutical company focused on developing innovative products in oncology, immunology, and hematology, cardiovascular. In November 2020, BMS received EC’s approval for Opdivo + Yervoy with two cycles of CT for 1L treatment of mNSCLC. BMS’ Revlimid recorded total sales of $12.10B while the company generated total revenue of $28.14B from its oncology segment.

Source: Company annual reports, SEC filings, press releases, and company websites

Market Cap source: Google finance (as of 09^th September 2021)

All revenues are reported in USD.

Related Post: Top 20 Oncology Companies by Total Products